A new vaccine called Provenge has just been accepted by the FDA, making it the first to be approved by the agency for men fighting advanced prostate cancer. While Provenge is not a cure, it has shown promise in extending the lives of patients.

The treatment won’t come cheap, however, at $93,000 per patient. –JCL

The BBC:

A “vaccine” which harnesses the body’s own immune system to fight prostate cancer has been approved for use by US drug regulators.

Provenge — which is designed to be used in men with advanced disease — is the first of its kind to be accepted by the Food and Drug Administration.

Each dose has to be individually tailored and it is an expensive treatment at $93,000 per patient.

It will add to, rather than replace, existing treatments, said experts.

Read more

 Your support matters…

Independent journalism is under threat and overshadowed by heavily funded mainstream media.

You can help level the playing field. Become a member.

Your tax-deductible contribution keeps us digging beneath the headlines to give you thought-provoking, investigative reporting and analysis that unearths what's really happening- without compromise.

Give today to support our courageous, independent journalists.

SUPPORT TRUTHDIG
In this Article:
#cancer#chemotherapy#fda#health#vaccine